As of 2024-12-13, the EV/EBITDA ratio of Avidity Biosciences Inc (RNA) is -11.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Avidity's latest enterprise value is 3,657.72 mil USD. Avidity's TTM EBITDA according to its financial statements is -322.60 mil USD. Dividing these 2 quantities gives us the above Avidity EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 17.3x | 16.0x |
| Forward P/E multiples | 15.3x - 23.1x | 15.7x |
| Fair Price | (38.27) - (43.62) | (39.75) |
| Upside | -213.3% - -229.2% | -217.8% |
| Date | EV/EBITDA |
| 2024-12-11 | -12.04 |
| 2024-12-10 | -12.20 |
| 2024-12-09 | -12.48 |
| 2024-12-06 | -13.01 |
| 2024-12-05 | -12.49 |
| 2024-12-04 | -12.88 |
| 2024-12-03 | -13.08 |
| 2024-12-02 | -14.13 |
| 2024-11-29 | -14.77 |
| 2024-11-27 | -14.88 |
| 2024-11-26 | -15.05 |
| 2024-11-25 | -15.54 |
| 2024-11-22 | -14.85 |
| 2024-11-21 | -14.59 |
| 2024-11-20 | -15.00 |
| 2024-11-19 | -14.85 |
| 2024-11-18 | -14.15 |
| 2024-11-15 | -14.45 |
| 2024-11-14 | -17.33 |
| 2024-11-13 | -18.27 |
| 2024-11-12 | -16.14 |
| 2024-11-11 | -16.28 |
| 2024-11-08 | -16.13 |
| 2024-11-07 | -16.42 |
| 2024-11-06 | -16.32 |
| 2024-11-05 | -15.53 |
| 2024-11-04 | -15.43 |
| 2024-11-01 | -14.34 |
| 2024-10-31 | -14.48 |
| 2024-10-30 | -14.84 |
| 2024-10-29 | -15.34 |
| 2024-10-28 | -15.76 |
| 2024-10-25 | -15.54 |
| 2024-10-24 | -15.55 |
| 2024-10-23 | -15.64 |
| 2024-10-22 | -16.38 |
| 2024-10-21 | -16.13 |
| 2024-10-18 | -17.51 |
| 2024-10-17 | -16.80 |
| 2024-10-16 | -16.95 |
| 2024-10-15 | -16.12 |
| 2024-10-14 | -16.13 |
| 2024-10-11 | -16.09 |
| 2024-10-10 | -15.21 |
| 2024-10-09 | -15.78 |
| 2024-10-08 | -15.99 |
| 2024-10-07 | -15.11 |
| 2024-10-04 | -16.35 |
| 2024-10-03 | -16.25 |
| 2024-10-02 | -16.28 |